Cargando…

URB2 as an important marker for glioma prognosis and immunotherapy

Introduction: Glioma is the most common primary brain tumor and primary malignant tumor of the brain in clinical practice. Conventional treatment has not significantly altered the prognosis of patients with glioma. As research into immunotherapy continues, glioma immunotherapy has shown great potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Chaoyou, Zhang, Zeyu, Han, Yongquan, Xu, Houshi, Zhu, Zhengyang, Du, Yichao, Hou, Pinpin, Yuan, Ling, Shao, Anwen, Zhang, Anke, Lou, Meiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080038/
https://www.ncbi.nlm.nih.gov/pubmed/37033651
http://dx.doi.org/10.3389/fphar.2023.1113182
_version_ 1785020837524406272
author Fang, Chaoyou
Zhang, Zeyu
Han, Yongquan
Xu, Houshi
Zhu, Zhengyang
Du, Yichao
Hou, Pinpin
Yuan, Ling
Shao, Anwen
Zhang, Anke
Lou, Meiqing
author_facet Fang, Chaoyou
Zhang, Zeyu
Han, Yongquan
Xu, Houshi
Zhu, Zhengyang
Du, Yichao
Hou, Pinpin
Yuan, Ling
Shao, Anwen
Zhang, Anke
Lou, Meiqing
author_sort Fang, Chaoyou
collection PubMed
description Introduction: Glioma is the most common primary brain tumor and primary malignant tumor of the brain in clinical practice. Conventional treatment has not significantly altered the prognosis of patients with glioma. As research into immunotherapy continues, glioma immunotherapy has shown great potential. Methods: The clinical data were acquired from the Chinese Glioma Genome Atlas (CGGA) database and validated by the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) dataset, Clinical Proteomic Tumor Analysis Consortium (CPTAP) database, and Western blot (WB) analysis. By Cox regression analyses, we examined the association between different variables and overall survival (OS) and its potential as an independent prognostic factor. By constructing a nomogram that incorporates both clinicopathological variables and the expression of URB2, we provide a model for the prediction of prognosis. Moreover, we explored the relationship between immunity and URB2 and elucidated its underlying mechanism of action. Results: Our study shows that URB2 likely plays an oncogenic role in glioma and confirms that URB2 is a prognostic independent risk factor for glioma. Furthermore, we revealed a close relationship between immunity and URB2, which suggests a new approach for the immunotherapy of glioma. Conclusion: URB2 can be used for prognosis prediction and immunotherapy of glioma.
format Online
Article
Text
id pubmed-10080038
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100800382023-04-08 URB2 as an important marker for glioma prognosis and immunotherapy Fang, Chaoyou Zhang, Zeyu Han, Yongquan Xu, Houshi Zhu, Zhengyang Du, Yichao Hou, Pinpin Yuan, Ling Shao, Anwen Zhang, Anke Lou, Meiqing Front Pharmacol Pharmacology Introduction: Glioma is the most common primary brain tumor and primary malignant tumor of the brain in clinical practice. Conventional treatment has not significantly altered the prognosis of patients with glioma. As research into immunotherapy continues, glioma immunotherapy has shown great potential. Methods: The clinical data were acquired from the Chinese Glioma Genome Atlas (CGGA) database and validated by the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) dataset, Clinical Proteomic Tumor Analysis Consortium (CPTAP) database, and Western blot (WB) analysis. By Cox regression analyses, we examined the association between different variables and overall survival (OS) and its potential as an independent prognostic factor. By constructing a nomogram that incorporates both clinicopathological variables and the expression of URB2, we provide a model for the prediction of prognosis. Moreover, we explored the relationship between immunity and URB2 and elucidated its underlying mechanism of action. Results: Our study shows that URB2 likely plays an oncogenic role in glioma and confirms that URB2 is a prognostic independent risk factor for glioma. Furthermore, we revealed a close relationship between immunity and URB2, which suggests a new approach for the immunotherapy of glioma. Conclusion: URB2 can be used for prognosis prediction and immunotherapy of glioma. Frontiers Media S.A. 2023-03-24 /pmc/articles/PMC10080038/ /pubmed/37033651 http://dx.doi.org/10.3389/fphar.2023.1113182 Text en Copyright © 2023 Fang, Zhang, Han, Xu, Zhu, Du, Hou, Yuan, Shao, Zhang and Lou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Fang, Chaoyou
Zhang, Zeyu
Han, Yongquan
Xu, Houshi
Zhu, Zhengyang
Du, Yichao
Hou, Pinpin
Yuan, Ling
Shao, Anwen
Zhang, Anke
Lou, Meiqing
URB2 as an important marker for glioma prognosis and immunotherapy
title URB2 as an important marker for glioma prognosis and immunotherapy
title_full URB2 as an important marker for glioma prognosis and immunotherapy
title_fullStr URB2 as an important marker for glioma prognosis and immunotherapy
title_full_unstemmed URB2 as an important marker for glioma prognosis and immunotherapy
title_short URB2 as an important marker for glioma prognosis and immunotherapy
title_sort urb2 as an important marker for glioma prognosis and immunotherapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080038/
https://www.ncbi.nlm.nih.gov/pubmed/37033651
http://dx.doi.org/10.3389/fphar.2023.1113182
work_keys_str_mv AT fangchaoyou urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT zhangzeyu urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT hanyongquan urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT xuhoushi urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT zhuzhengyang urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT duyichao urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT houpinpin urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT yuanling urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT shaoanwen urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT zhanganke urb2asanimportantmarkerforgliomaprognosisandimmunotherapy
AT loumeiqing urb2asanimportantmarkerforgliomaprognosisandimmunotherapy